Use: Labeled indications
- INDICATIONS AND USAGE IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor.
- induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or…
Full indications and usage US FDA label
INDICATIONS AND USAGE IMPORTANT NOTICE: Oxytocin Injection, USP (synthetic) is indicated for the medical rather than the elective induction of labor. Available data and information are inadequate to define the benefits to risks considerations in the use of the drug product for elective induction. Elective induction of labor is defined as the initiation of labor for convenience in an individual with a term pregnancy who is free of medical indications.
Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion.
In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.
Antepartum Oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable, in order to achieve early vaginal delivery for fetal or maternal reasons. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, pre-eclampsia at or near term, when delivery is in the best interest of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) adjunctive therapy in the management of incomplete or inevitable abortion.
In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases.
Postpartum Oxytocin injection (synthetic) is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.
Contraindications
CONTRAINDICATIONS Oxytocin injection (synthetic) is contraindicated in any of the following conditions:
- Significant cephalopelvic disproportion;
- Unfavorable fetal positions or presentations which are undeliverable without conversion prior to delivery, i.e., transverse lies;
- In obstetrical emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention;
- In cases of fetal distress where delivery is not imminent;
- Prolonged use in uterine inertia or severe toxemia;
- Hypertonic uterine patterns;
- Patients with hypersensitivity to the drug;
- Induction or augmentation of labor in those cases where vaginal delivery is contraindicated, such as cord presentation or prolapse, total placenta previa, and vasa previa.
Dosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Dosage of oxytocin is determined by uterine response. The following dosage information is based upon the various regimens and indications in general use. Induction or Stimulation of Labor Intravenous infusion (drip method) is the only acceptable method of administration for the induction or stimulation of labor.
Accurate control of the rate of infusion flow is essential. An infusion pump or other such device and frequent monitoring of strength of contractions and fetal heart rate are necessary for the safe administration of oxytocin for the induction or stimulation of labor. If uterine contractions become too powerful, the infusion can be abruptly stopped, and oxytocic stimulation of the uterine musculature will soon wane.
An intravenous infusion of a non-oxytocin containing solution should be started. Physiologic electrolyte solutions should be used except under unusual circumstances. To prepare the usual solution for intravenous infusion–one mL (10 units) is combined aseptically with 1,000 mL of a non-hydrating diluent. The combined solution, rotated in the infusion bottle to insure thorough mixing, contains 10 mU/mL.
Add the container with dilute oxytocic solution to the system through the use of a constant infusion pump or other such device to control accurately the rate of infusion. The initial dose should be no more than 1 to 2 mU/min. The dose may be gradually increased in increments of no more than 1 to 2 mU/min., until a contraction pattern has been established which is similar to normal labor.
The fetal heart rate, resting uterine tone, and the frequency, duration, and force of contractions should be monitored. The oxytocin infusion should be discontinued immediately in the event of uterine hyperactivity or fetal distress. Oxygen should be administered to the mother. The mother and fetus must be evaluated by the responsible physician.
Control of Postpartum Uterine Bleeding Intravenous Infusion (Drip Method )—To control postpartum bleeding, 10 to 40 units of oxytocin may be added to 1,000 mL of a nonhydrating diluent and run at a rate necessary to control uterine atony. Intramuscular Administration —1 mL (10 units) of oxytocin can be given after delivery of the placenta.
Treatment of Incomplete or Inevitable Abortion Intravenous infusion with physiologic saline solution, 500 mL, or 5% dextrose in physiologic saline solution to which 10 units of oxytocin have been added should be infused at a rate of 20 to 40 drops/minute. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Induction or Stimulation of Labor Intravenous infusion (drip method) is the only acceptable method of administration for the induction or stimulation of labor. Accurate control of the rate of infusion flow is essential. An infusion pump or other such device and frequent monitoring of strength of contractions and fetal heart rate are necessary for the safe administration of oxytocin for the induction or stimulation of labor.
If uterine contractions become too powerful, the infusion can be abruptly stopped, and oxytocic stimulation of the uterine musculature will soon wane. An intravenous infusion of a non-oxytocin containing solution should be started. Physiologic electrolyte solutions should be used except under unusual circumstances. To prepare the usual solution for intravenous infusion–one mL (10 units) is combined aseptically with 1,000 mL of a non-hydrating diluent.
The combined solution, rotated in the infusion bottle to insure thorough mixing, contains 10 mU/mL. Add the container with dilute oxytocic solution to the system through the use of a constant infusion pump or other such device to control accurately the rate of infusion. The initial dose should be no more than 1 to 2 mU/min.
The dose may be gradually increased in increments of no more than 1 to 2 mU/min., until a contraction pattern has been established which is similar to normal labor. The fetal heart rate, resting uterine tone, and the frequency, duration, and force of contractions should be monitored. The oxytocin infusion should be discontinued immediately in the event of uterine hyperactivity or fetal distress.
Oxygen should be administered to the mother. The mother and fetus must be evaluated by the responsible physician.
Control of Postpartum Uterine Bleeding Intravenous Infusion (Drip Method )—To control postpartum bleeding, 10 to 40 units of oxytocin may be added to 1,000 mL of a nonhydrating diluent and run at a rate necessary to control uterine atony. Intramuscular Administration —1 mL (10 units) of oxytocin can be given after delivery of the placenta.
Treatment of Incomplete or Inevitable Abortion Intravenous infusion with physiologic saline solution, 500 mL, or 5% dextrose in physiologic saline solution to which 10 units of oxytocin have been added should be infused at a rate of 20 to 40 drops/minute. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Solution for injection: 5 IU/mL, 10 IU per mL, 10 IU/mL
- Concentrate for solution for injection: 5 IU per mL
Registered products in the Philippines
55 products registered with the Food and Drug Administration (FDA) Philippines list Oxytocin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products55
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcutocinOxytocin | 10 IU/mL Solution for Injection (I.M./I.V./S.C.)1 mL USP Type I clear glass ampoule with snap of brown band in 5 PVC trays x 10's (Box of 50's) | Rx | Aculife Healthcare Private LimitedIndia | Blue Global (FZE) | DRP-12831 | Oct 13, 2027 | |
AeoxOxytocin | 10 IU / mL Solution for Injection (I.M/I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10's) | Rx | Umedica Laboratories Pvt. Ltd.India | Dynasty PharmaceuticalsImporter: Suhitas Pharmaceuticals Inc. | DRP-4985-08 | Dec 11, 2028 | |
AmbitocynOxytocin | 10 IU/mL Solution for Injection1 mL USP Type I Amber glass ampoule (Box of 5's) | Rx | Sanjivani Paranteral Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-6317-02 | Jan 12, 2028 | |
AmbitoxOxytocin | 10 I.U./mL Solution for Injection (IV)Clear and Colorless Glass Ampoule x 1 mL in a Blister Tray (Box of 10’s) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DR-XY40469 | Jan 2, 2030 | |
AmbtocynOxytocin | 10 I.U. / mL Solution for Injection (I.M./I.V.)1 mL Type I Clear and Colorless Glass Ampoule in Clear PVC Tray (Box of 10's) | Rx | Ma'anshan BBCA Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8474 | Mar 18, 2031 | |
ArkocinOxytocin | 10 IU/mL Solution for Injection (I.M./I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Ark Gen Pharma Corp.Importer: Suhitas Pharmaceuticals Inc. | DRP-4985-04 | Dec 11, 2028 | |
AshxytinOxytocin | 10 IU/mL Solution for Injection1 mL USP Type I Amber glass ampoule (Box of 5's) | Rx | Sanjivani Paranteral Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-6317-07 | Jan 12, 2028 | |
AshxytinOxytocin | 10 IU/mL Solution for Injection (I.M./I.V.)1 mL USP Type I Amber Glass Ampoule (Box of 5's) | Rx | Apoorv InternationalIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-6317-06 | Jan 12, 2028 | |
CleartocinOxytocin | 10 IU/mL Solution for Injection1 mL USP Type I Amber glass ampoule (Box of 5's) | Rx | Sanjivani Paranteral Ltd.India | CV Clearvue Pharma, Inc.Importer: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-6317-04 | Jan 12, 2028 | |
DynoxOxytocin | 10 I.U./ml Solution for Injection (I.M./I.V.)1 ml Type I Clear and Colorless Glass Ampoule in Clear PVC Tray (Box of 10’s) | Rx | Ma'anshan BBCA Pharmaceutical Co., Ltd.China | Dynasty PharmaceuticalsImporter: Amb Hk Enterprises Inc. | DRP-8474-03 | Apr 23, 2031 | |
ErgitocinOxytocin | 10 IU/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL (Box of 10's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Medlane Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9991-01 | May 13, 2031 | |
EvatocinOxytocin | 10 IU/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1mL (Box of 10's) | Rx | Neon Laboratories LimitedIndia | Elin Pharmaceuticals, Inc. | DR-XY25834 | Sep 19, 2031 | |
EvexyOxytocin | 10 IU/mL Solution for Injection (IM/IV Infusion)Type I Hydrolytic Resistant Glass Colourless Borosilicate Glass Ampoule X 1 mL (Net Content) (Box of 10's) | Rx | HBM Pharma S.R.O.Slovak Republic | Tamiga Pharmaceuticals SupplyImporter: Ambica International CorporationTrader: JSC Grindeks | DRP-8748 | Feb 21, 2030 | |
ExatoxynOxytocin | 10 IU/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL (Box of 10's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9991-02 | May 13, 2031 | |
ExertaOxytocin | 10 IU/mL Solution for Injection (I.M/I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-4985-03 | Dec 11, 2028 | |
FetusinOxytocin | 10 IU/mL Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 1 mL (net content). Box of 10's. | Rx | Sterile-Gene Life Sciences (P) Ltd.India | Vamsler Phils. Inc.Importer: Euro-Health Care Exponents, Inc. | DRP-12552 | Sep 1, 2027 | |
GentocinOxytocin | 10 IU /mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 1mL (Box of 10's) | Rx | MERCURY LABORATORIES LTD.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-8202-01 | Nov 17, 2028 | |
GentoxynOxytocin | 10 IU /mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 1 mL Box of 10's | Rx | Mercury Laboratories Ltd.India | GA2 Pharmaceutical IncImporter: MEDINOVA PHARMACEUTICAL INC. | DRP-8202-02 | Nov 17, 2028 | |
GocynOxytocin | 10 I.U./mL Solution for Injection (I.M./I.V.)1 mL Type I clear and colorlress glass ampoule in Clear PVC tray (Box of 10's) | Rx | Ma'anshan BBCA Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-8474-02 | Apr 16, 2031 | |
GoxitocinOxytocin | 10 IU/mL Solution for Injection (I.M./I.V.)1 mL USP Type I Amber glass ampoule (Box of 5's) | Rx | Apoorv InternationalIndia | Applied Pharmaceuticl Distribution Inc.Importer: Ambica International Corporation | DRP-6317-05 | Jan 12, 2028 | |
Goxy InjOxytocin | 10 IU/mL Solution for Injection (I.M/I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-4985-06 | Dec 11, 2028 | |
GreatocynOxytocin | 10 I.U./mL Solution for I.V. Injection (I.M./I.V. Infusion)USP Type I glass ampoule x 1 mL (net content) (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-10762-01 | Nov 16, 2031 | |
Gyne-TocinOxytocin | 10 IU/mL Solution for Injection (IM/IV)USP Type 1 Clear Glass Ampoule x 1 mL (Box of 10's) | Rx | Harmann Pharmaceutical Laboratories (Pvt) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9991 | Apr 21, 2031 | |
ImfetusOxytocin | 10 I.U./mL Solution for Injection (I.V.)USP Type I Clear and Colorless Glass Ampoule x 1 mL in a Plastic Tray (Box of 10's) | Rx | Sterile-Gene Life Sciences (P) Ltd.India | Vamsler Phils. Inc.Importer: Lloyd Laboratories, Inc. | DR-XY47521 | Dec 9, 2026 | |
LavoxinOxytocin | 10 IU / mL Solution for Injection (IM/IV Infusion)Type I Hydrolytic Resistant Glass Colourless Borosilicate Glass Ampoule x 1 mL (Net Content) (Box of 10’s) | Rx | HBM Pharma S.R.O.Slovak Republic | Scheeling, Inc.Importer: Ambica International CorporationTrader: JSC Grindeks | DRP-8748-01 | Feb 21, 2030 | |
LavoxinOxytocin | 10 IU/mL Solution for Injection1 mL USP Type I Amber Glass Ampoule (Box of 5's) | Rx | Sanjivani Paranteral Ltd.India | Scheeling, Inc.Importer: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-6317-01 | Jan 12, 2028 | |
NoneOxytocin | 10 IU/mL Solution for Injection (I.M/I.V./S.C.)1 mL USP Type I Clear Glass Ampoule x 1’s (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Excelcare, IncImporter: Suhitas Pharmaceuticals Inc. | DRP-4985-02 | Dec 11, 2028 | |
NoneOxytocin | 10 IU/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL (Box of 10's) | Rx | Maanshan BBCA Pharmaceutical Co., Ltd.China | Endure Medical Inc. | DR-XY44219 | Feb 26, 2030 | |
ObcinOxytocin | 10 I.U./mL Solution for Injection (I.M./I.V.)Type I Clear Glass Ampoule in 1 mL (net content) (Box of 10's and 100’s) | Rx | PT. Sanbe Farma (Unit 3)Indonesia | Phoenix Pharmaceutical, Inc. | DR-XY46164 | Nov 22, 2027 | |
OcitoxinOxytocin | 10 IU/mL Solution for Injection1 mL USP Type I Amber glass ampoule (Box of 5's) | Rx | Sanjivani Paranteral Ltd.India | Virrod Inc.Importer: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-6317-03 | Jan 12, 2028 | |
OratocinOxytocin | 10 IU/mL Solution for Injection (I.M./I.V./S.C)USP Type I Clear Glass Ampoule x 1 mL (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-4985-09 | Dec 11, 2028 | |
Oxitin-10Oxytocin | 10 IU/mL Solution for Injection1 mL USP Type I Amber glass ampoule (Box of 5's) | Rx | Sanjivani Paranteral Ltd.India | Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-6317 | Jan 12, 2028 | |
OxitoneOxytocin | 10 I.U./mL Solution for Injection (I.M./I.V.)1 mL clear ampoule (Box of 25's) | Rx | Harson LaboratoriesIndia | Phil. Pharmawealth, Inc. | DRP-3114 | Sep 4, 2027 | |
OxtimonOxytocin | 10 I.U. /mL Solution for InjectionType I Clear Colorless Glass Ampoule x 1 mL (Box of 10's) | Rx | Panpharma GmbHGermany | Duopharma Trade Phils., Inc. | DRP-464 | Dec 7, 2030 | |
OxtolevOxytocin | 10 IU/mL Solution for Injection (I.M/I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-4985-05 | Dec 11, 2028 | |
OxycareOxytocin | 10 I.U./mL Solution for I.V. Injection (I.M./I.V. Infusion)USP Type I glass ampoule x 1 mL (net content) (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Euro-Care Products Philippines | DRP-10762 | Nov 16, 2031 | |
OxycinOxytocin | 10 IU/mL Solution for Injection (IM/IV Infusion)Type I glass vial x 1 mL (net content) with grey bromobutyl rubber stopper, aluminum seal, and blue flip-off cap (Box of 10's) | Rx | SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.China | Luoxin Pharmaceuticals (PH) Corp. | DR-XY49450 | Jul 15, 2030 | |
OxycoreOxytocin | 10 I.U./mL Solution for Injection (I.V./I.M./S.C.)1 mL-net content USP Type I clear and colorless glass ampoule (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Greencore Pharma, Inc. | DRP-14663 | Nov 17, 2028 | |
OxyfarOxytocin | 10 IU/mL Solution for Injection (IV)2 mL USP Type I Clear Glass Vial (Box of 1's) | Rx | Scott-Edil Pharmacia LimitedIndia | PHARMAKON BIOTEC INC. | DRP-7402 | Oct 12, 2027 | |
OxylaOxytocin | 10 I.U./ mL Solution for Injection (I.M. / I.V.)Type I (Borosilicate) Clear Glass Ampoule in 1ml (net content) (Box of 10 ampoules) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY45566 | Aug 19, 2031 | |
Oxyt 10Oxytocin | 10 IU/mL Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 1 mL in White Opaque High Impact Polystyrene (HIPS) Tray (Box of 10's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Synergen Pharma Inc.Trader: Synergen Asia Pte. Ltd. | DR-XY47841 | Mar 30, 2029 | |
Oxyt 5Oxytocin | 5 IU/mL Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 1 mL in White Opaque HIPS Tray (Box of 10's) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Synergen Pharma IncTrader: Synergen Asia Pte. Ltd. | DR-XY47842 | Mar 30, 2029 | |
OxytocyOxytocin | 10 I.U. / mL Solution for Injection (I.M./I.V.)1 mL Type I Clear and Colorless Glass Ampoule in Clear PVC Tray (Box of 10's) | Rx | Ma'anshan BBCA Pharmaceutical Co., Ltd.P.R. of China | Cyden Medicale Trading Inc.Importer: AMB HK Enterprises Inc. | DRP-8474-05 | Mar 18, 2031 | |
OxytovinOxytocin | 10 IU/mL Solution for Injection (I.M./I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | MDB Pharma TradingImporter: Suhitas Pharmaceuticals Inc. | DRP-4985-10 | Dec 11, 2028 | |
PopicinOxytocin | 10 IU/mL Solution for Injection (I.M/I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-4985 | Dec 11, 2028 | |
RifoxynOxytocin | 10 IU/mL Solution for Injection (I.M./I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10's) | Rx | Umedica Laboratories Pvt. Ltd.India | Rifemedica CorporationImporter: Suhitas Pharmaceuticals Inc. | DRP-4985-07 | Dec 11, 2028 | |
RoxipanOxytocin | 10 I.U Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL (Box of 10's) | Rx | Rotexmedica GmbHGermany | Panpharma Healthcare and Pharmaceuticals Inc. | DR-XY32916 | Jan 31, 2027 | |
SoloxineOxytocin | 10 IU/mL Solution for Injection (I.M/I.V./S.C.)USP Type I Clear Glass Ampoule x 1 mL (Box of 10’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Innogen Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-4985-01 | Dec 11, 2028 | |
SyntocinonOxytocin | 10 I.U./mL Solution for Injection (I.M./I.V. Infusion)Type I colorless glass ampoule x 1 mL in PVC tray (Box of 10's) | Rx | Sovereign Pharma Private LimitedIndia | Viatris Pharmaceuticals, Inc. | DRP-1981 | Sep 27, 2029 | |
SyntomaxOxytocin | 10 IU/mL Solution For Injection (IM/IV)1 mL clear Type I glass ampoule (Box of 50's and 10's) | Rx | Indus Pharma (Pvt.) Ltd.Pakistan | One Dexcel Pharma Inc | DRP-13669 | Mar 23, 2028 | |
SyntomaxOxytocin | 5 IU per mL Concentrate for Solution for Injection (IV)1 mL USP Type I Clear Glass Ampoule (Box of 50's) | Rx | Indus Pharma (Pvt.) Ltd.Pakistan | One Dexcel Pharma Inc. | DRP-11844 | May 6, 2027 | |
TocinoxOxytocin | 10 IU per mL Solution for Injection (IM/IV)Clear Glass Ampoule x 1 mL (Box of 1 Blister pack x 10's) | Rx | GEOFMAN PHARMACEUTICALSPakistan | SAHAR INTERNATIONAL TRADING INC. | DRP-973 | Sep 27, 2027 | |
UtexynOxytocin | 10 IU/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 1 mL (Box of 10's) | Rx | Gland Pharma LimitedIndia | Importer: Endure Medical, Inc. | DR-XY43010 | Nov 21, 2028 | |
XetocinOxytocin | 10 IU / mL Solution for Injection (I.M./I.V.)1 mL clear Type I glass ampoule (Box of 50's and 10's) | Rx | Indus Pharma (Pvt.) Ltd.Pakistan | Ellebasy Medicale Group Inc.Importer: One Dexcel Pharma Inc. | DRP-13669-01 | Mar 23, 2028 | |
XyntocOxytocin | 10 IU /mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 1 mL (Box of 10's) | Rx | Mercury Laboratories Ltd.India | Medinova Pharmaceutical Inc. | DRP-8202 | Nov 17, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Oxytocin injection (synthetic) when given for induction or stimulation of labor, must be administered only by the intravenous route and with adequate medical supervision in a hospital.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following adverse reactions have been reported in the mother:
- Anaphylactic reaction
- Postpartum hemorrhage
- Cardiac arrhythmia
- Fatal afibrinogenemia
- Nausea
- Vomiting
- Premature ventricular contractions
- Pelvic hematoma Excessive dosage or hypersensitivity to the drug may result in uterine hypertonicity, spasm, tetanic contraction or rupture of the uterus. The possibility of increased blood loss and afibrinogenemia should be kept in mind when administering the drug. Severe water intoxication with convulsions and coma has occurred, and is associated with a slow oxytocin infusion over a 24-hour period. Maternal death due to oxytocin-induced water intoxication has been reported. The following adverse reactions have been reported in the fetus or infant: Due to induced uterine mobility:
- Bradycardia
- Premature ventricular contractions and other arrhythmias
- Permanent CNS or brain damage
- Fetal death Due to use of oxytocin in the mother:
- Neonatal retinal hemorrhage
- Low Apgar scores at five minutes
- Neonatal jaundice
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Oxytocin injection (synthetic) acts on the smooth muscle of the uterus to stimulate contractions; response depends on the uterine threshold of excitability. It exerts a selective action on the smooth musculature of the uterus, particularly toward the end of pregnancy, during labor and immediately following delivery.
Oxytocin stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions and raises the tone of the uterine musculature. Synthetic oxytocin does not possess the cardiovascular effects, such as elevation of blood pressure, as exhibited by vasopressin found in posterior pituitary injection.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Oxytocin 10 IU/mL, 1 mL Ampule | ₱4.93–₱44.98Reference ₱7.12 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Oxytocin (synthetic) |
| PNF listing | Inj.: 10 IU/mL, 1 mL ampul (IM, IV)Restrictions: Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Oxytocin · Fresenius Kabi USA, LLC [US FDA-approved label, version 7, January 12, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7fd585a-99b7-4309-b003-a6cbef05372c
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .